Business Context and Reporting Period
This Form 8-K was filed by ChromaDex Corporation (not Niagen Bioscience, Inc.) on June 19, 2015, reporting events occurring on June 17, 2015. The filing details an amendment to an existing material definitive agreement regarding a term loan facility.
Key Financial Metrics and Debt Structure
- Total Loan Facility: Up to $5 million.
- Funding Status: The first $2.5 million was funded at the original closing (September 29, 2014). The remaining $2.5 million (second advance) was funded on June 18, 2015, triggering the amendment's effectiveness.
- Interest-Only Period: Extended to March 31, 2016. This period may be extended to June 30, 2016, if consolidated revenue reaches $11.5 million for the six months ending December 31, 2015.
- Repayment Terms: Principal repayment in equal monthly installments begins after the interest-only period, with a maturity date of April 1, 2018.
- Costs: A nonrenewable facility fee of $15,000 was paid to the agent upon funding the second advance.
Material Changes Versus Prior Period
The primary change is the extension of the interest-only period from the original October 31, 2015, deadline to March 31, 2016. Additionally, the filing confirms the full drawdown of the $5 million facility, whereas previously only half was funded. The filing does not provide comparative revenue or profit figures for the current period versus the prior period.
Guidance, Outlook, and Risks
The filing establishes a performance-based contingency for the loan terms: achieving $11.5 million in consolidated revenue for the six months ending December 31, 2015, is required to extend the interest-only period to June 30, 2016. No specific forward-looking revenue guidance or management commentary on future operations is provided in this text. The filing notes that the agreement terms are qualified by the complete text of the exhibits.
Investor Verification Checklist
- Verify the company name is ChromaDex Corporation, not Niagen Bioscience, Inc.
- Confirm the total outstanding debt is now $5 million following the second advance.
- Monitor revenue performance for the six months ending December 31, 2015, to determine if the interest-only period extends to June 2016.
- Review the full text of Exhibit 10.1 (Amendment No. 1) for specific interest rates and covenants not detailed in this summary.